

|  |                        |               |
|--|------------------------|---------------|
| <b>INFORMATION DISCLOSURE STATEMENT<br/>BY APPLICANT</b> | Attorney Docket Number | 6947-75756-01 |
|  | Application Number     | 10/579,606    |
|  | Filing Date            | May 16, 2006  |
|  | First Named Inventor   | Brown         |
|  | Art Unit               |               |
|  | Examiner Name          |               |

#### **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number    | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|-----------|------------------|-------------------------------|
|                      |                     | 5,922,576 | 07/13/1999       | He <i>et al.</i>              |
|                      |                     | 6,573,090 | 06/03/2003       | Breakefield <i>et al.</i>     |

#### **FOREIGN PATENT DOCUMENTS**

| Examiner's Initials* | Cite No. (optional) | Country | Number       | Publication Date | Name of Applicant or Patentee  |
|----------------------|---------------------|---------|--------------|------------------|--|
|                      |                     | Europe  | EP 0 353 851 | 02/07/1990       | National Research Development Corporation                            |
|                      |                     | Europe  | EP 0 538 496 | 04/28/1993       | Immuno Immuno Aktiengesellschaft                                     |
|                      |                     | Europe  | EP 0 753 581 | 01/15/1997       | Immuno AG  |
|                      |                     | PCT     | WO 95/04139  | 02/09/1995       | The Wistar Institute of Anatomy and Biology                          |
|                      |                     | PCT     | WO 96/05291  | 02/22/1996       | Syntro Corporation   |
|                      |                     | PCT     | WO 97/04804  | 02/13/1997       | American Cyanamid Company  |
|                      |                     | PCT     | WO 97/14808  | 04/24/1997       | St Jude Children's Research Hospital                                 |
|                      |                     | PCT     | WO 98/51809  | 11/19/1998       | University of Pittsburgh The Commonwealth System of Higher Education |
|                      |                     | PCT     | WO 99/55345  | 11/04/1999       | The General Hospital Corporation                                     |
|                      |                     | PCT     | WO 01/16331  | 03/08/2001       | The General Hospital Corporation                                     |
|                      |                     | PCT     | WO 01/46449  | 06/28/2001       | Biovex Ltd   |

|                        |                     |
|------------------------|---------------------|
| EXAMINER<br>SIGNATURE: | DATE<br>CONSIDERED: |
|------------------------|---------------------|

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

|  |  |                        |               |
|--|--|------------------------|---------------|
| <b>INFORMATION DISCLOSURE STATEMENT<br/>BY APPLICANT</b> |  | Attorney Docket Number | 6947-75756-01 |
|  |  | Application Number     | 10/579,606    |
|  |  | Filing Date            | May 16, 2006  |
|  |  | First Named Inventor   | Brown         |
|  |  | Art Unit               |               |
|  |  | Examiner Name          |               |

**FOREIGN PATENT DOCUMENTS**

| Examiner's Initials* | Cite No. (optional) | Country | Number      | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|---------|-------------|------------------|-------------------------------|
|                      |                     | PCT     | WO03/018788 | 03/06/2003       | ML Laboratories PLC           |

**OTHER DOCUMENTS**

|                      |                     |   |
|----------------------|---------------------|---|
| Examiner's Initials* | Cite No. (optional) | Liu <i>et al.</i> , "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties," <i>Gene Therapy</i> 10:292-303 (2003)                                       |
|                      |                     | Gomez-Lira <i>et al.</i> , "CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers," <i>Journal of Neurommunology</i> 140:216-221 (2003)              |
|                      |                     | McNeish <i>et al.</i> , "Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered <i>E. coli</i> nitroreductase and CB1954," <i>Gene Therapy</i> 5:1061-1069 (1998) |
|                      |                     | Varghese <i>et al.</i> , "Oncolytic herpes simplex virus vectors for cancer virotherapy," <i>Cancer Gene Therapy</i> 9:967-978 (2002)   |
|                      |                     | Weedon <i>et al.</i> , "Sensitisation of human carcinoma cells to the prodrug cb1954 by adenovirus vector-mediated expression of <i>E. coli</i> nitroreductase," <i>Int. J. Cancer</i> 86:848-854 (2000)        |
|                      |                     |   |
|                      |                     |   |
|                      |                     |   |
|                      |                     |   |

|                     |                     |
|---------------------|---------------------|
| EXAMINER SIGNATURE: | DATE<br>CONSIDERED: |
|---------------------|---------------------|

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.